Ervin Braun, DMD
Dr. Ervin Braun has served as our Chief Executive Officer and as one of our directors since October 2012. Dr. Braun has also served as a Co-Founder and Managing Partner of Ceres Group Holdings, LLC since 2017 and had served on the board of directors of Ceres Acquisition Corp, and Frozen Food Partners. As a serial entrepreneur for over 30 years, Dr. Braun has developed a broad portfolio of investments, including investments through financial markets, angel investing, private equity, and real estate. Dr Braun received his Series 65 License in 2018 qualifying him as an Investment Advisor Representative (IAR).
He has also served as a consultant for several entertainment and social media companies, as well as advised on the development of Pencils of Promise, a highly visible and successful nonprofit organization.
Dr. Braun has over 28 years of clinical experience and advanced training in prosthodontics. He received his DMD from the University of Pennsylvania in 1978 and subsequently completed specialty training in Prosthodontics followed by a fellowship in Maxillo-Facial Prosthetics in 1982 at Memorial Sloan-Kettering Cancer Center.
Alain Klapholz, MBA
Mr. Klapholz is the founder of OptMed and serves as our Chief Technical Officer. He is also the COO of TissueMill Technologies, LLC. Over the past 26 years, Mr. Klapholz has served as a senior executive at a number of medical device companies, where he has contributed to product development, business development, and financing. He has successfully led several products through the FDA approval process. Mr. Klapholz received his B.A. in economics from Yeshiva University in 1977 and his M.B.A. in finance from the New York University – Leonard N. Stern School of Business in 1979.
H.F. Burrows, MBA, EMT, CWCA, BCMAS
Former executive with 30+ years of experience successfully developing and implementing strategic and tactical clinical, scientific, and commercial plans to launch and grow transformative medical devices. Mr. Burrows has amassed a proven track record of developing and launching disruptive products in the acute and chronic wound healing arena. He has successfully led multi-departmental teams in medical device and pharmaceutical companies, from Johnson & Johnson®, Gore®, and Smith+Nephew®, to smaller companies like MiMedx®, CryoLife®, Histogen®, and Advanced Tissue Sciences®.
H.F. has successfully launched and supported the growth of some of the most well-known wound healing products in the market, including EpiFix®, AmnioFix®, ReGranex®, Promogran®, Prizma®, and Dermagraft®. Mr. Burrows is formally trained as an EMT and holds certifications in wound care and medical affairs, and with his vast experience, he is uniquely qualified to help drive OptMed’s success.
Verónica de la Fuente, PhD
VP of R&D and Manufacturing
Former Lab Manager and Technology Developer at Afinitica Technologies and Afinitica Process Technologies; 12+ years of research, development and management experience in industrial chemistry.
Thomas Davenport, MD, FACS
Dr. Thomas Davenport has been a partner at Long Island Plastic Surgical Group since 2006. He received his MD degree from Yale University. He completed both his residency in General Surgery and fellowship in Plastic Surgery in the Harvard University Program at the Massachusetts General Hospital.
Dr. Davenport completed specialty training in Cancer Reconstruction and Cosmetic Surgery as a fellow at Memorial Sloan-Kettering Cancer Center. He completed his training in burn and accident reconstruction with Harvard University at the Shriner Burn Hospital for Children. Dr. Davenport specialises in treating complex wound problems, including wound care and burn reconstruction. Dr. Davenport is the division chief of plastic surgery and director of microsurgery at NYU Long Island Hospital. He has authored numerous articles and book chapters, lectures nationally and internationally on various aspects of plastic surgery, and consults for numerous companies.